Activation of human platelets by misfolded proteins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 7, 2007, Pages 1657-1665

  Herczenik, Eszter ^a   Bouma, Barend ^a,b   Korporaal, Suzanne J A ^a   Strangi, Remo ^b   Zeng, Qinghong ^c   Gros, Piet ^c   Van Eck, Miranda ^d   Van Berkel, Theo J C ^d   Gebbink, Martijn F B G ^a,b   Akkerman, Jan Willem N ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Amyloid; CD36; Glycoprotein Ib ; Platelet activation; sRAGE; Tissue plasminogen activator

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE DIPHOSPHATE; AMYLOID; CALCIUM ION; CD36 ANTIGEN; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FIBRINOGEN; GLYCOPROTEIN IB ALPHA; ILOPROST; INDOMETACIN; THROMBOXANE A2; TISSUE PLASMINOGEN ACTIVATOR;

ANTIGEN ANTIBODY REACTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENERGY CONSUMPTION; FEEDBACK SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

AMYLOID; ANTIGENS, CD36; BLOOD PLATELETS; CELLS, CULTURED; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; THROMBOXANE A2; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34250838086     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.143479     Document Type: Article

References (38)

1. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486-489.
2. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507-511.
3. Beyreuther K, Bush AI, Dyrks T, Hilbich C, Konig G, Monning U, Multhaup G, Prior R, Rumble B, Schubert W. Mechanisms of amyloid deposition in Alzheimer's disease. Ann N Y Acad Sci. 1991;640:129-139.
4. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS. Platelet activation in Alzheimer disease. Arch Neurol. 1998;55:530-536.
5. Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol. 2000;27:1-8.
6. Mori I, Kimura Y, Naiki H, Matsubara R, Takeuchi T, Yokochi T, Nishiyama Y. Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease. J Med Virol. 2004;73:605-611.
7. Ursini F, Davies KJ, Maiorino M, Parasassi T, Sevanian A. Atherosclerosis: another protein misfolding disease? Trends Mol Med. 2002;8:370-374.
8. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a conformational disease. JOP. 2005;6:287-302.
9. Buxbaum JN. The systemic amyloidoses. Curr Opin Rheumatol. 2004;16:67-75.
10. Stewart CR, Tseng AA, Mok YF, Staples MK, Schiesser CH, Lawrence LJ, Varghese JN, Moore KJ, Howlett GJ. Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. Biochemistry. 2005;44:9108-9116.
11. Korporaal SJ, Gorter G, van Rijn HJ, Akkerman JW. Effect of oxidation on the platelet-activating properties of low-density lipoprotein. Arterioscler Thromb Vasc Biol. 2005;25:867-872.
12. Kotronias D, Kapranos N. Herpes simplex virus as a determinant risk factor for coronary artery atherosclerosis and myocardial infarction. In Vivo. 2005;19:351-357.
13. Bouma B, Kroon-Batenburg LM, Wu YP, Brunjes B, Posthuma G, Kranenburg O, de Groot PG, Voest EE, Gebbink MF. Glycation induces formation of amyloid cross-beta structure in albumin. J Biol Chem. 2003;278:41810-41819.
14. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol. 2001;280:H1480-H1489.
15. Hausfater P, Costedoat-Chalumeau N, Amoura Z, Cacoub P, Papo T, Grateau G, Leblond V, Godeau P, Piette JC. AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol. 2005;34:315-319.
16. Halligan CS, Lacy MQ, Vincent RS, Dispenzieri A, Witzig TE, Lust JA, Fonseca R, Gertz MA, Kyle RA, Pruthi RK. Natural history of thromboembolism in AL amyloidosis. Amyloid. 2006;13:31-36.
17. Kranenburg O, Bouma B, Kroon-Batenburg LM, Reijerkerk A, Wu YP, Voest EE, Gebbink MF. Tissue-type plasminogen activator is a multi-ligand cross-beta structure receptor. Curr Biol. 2002;12:1833-1839.
18. Shehi E, Fusi P, Secundo F, Pozzuolo S, Bairati A, Tortora P. Temperature-dependent, irreversible formation of amyloid fibrils by a soluble human ataxin-3 carrying a moderately expanded polyglutamine stretch (Q36). Biochemistry. 2003;42:14626-14632.
19. Merlini G, Bellotti V, Andreola A, Palladini G, Obici L, Casarini S, Perfetti V. Protein aggregation. Clin Chem Lab Med. 2001;39:1065-1075.
20. Gasic-Milenkovic J, Dukic-Stefanovic S, uther-Conrad W, Gartner U, Munch G. Beta-amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon -gamma and 'advanced glycation endproducts' in a murine microglia cell line. Eur J Neurosci. 2003;17:813-821.
21. LeVine H, III. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404-410.
22. Soppitt GD, Pennock CA. Interaction of water-soluble amyloid fibrils with Congo Red and thioflavine T. Clin Chim Acta. 1969;26:165-166.
23. Wadenvik H, Kutti J. Effect of Iloprost (ZK 36 374), a novel prostacyclin analogue, on ADP-induced platelet aggregation. Acta Haematol. 1985;73:224-227.
24. Husemann J, Loike JD, Kodama T, Silverstein SC. Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J Neuroimmunol. 2001;114:142-150.
25. Deane R, Du YS, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907-913.
26. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El Khoury JB. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002;160:101-112.
27. Moir RD, Tanzi RE. LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP. Curr Alzheimer Res. 2005;2:269-273.
28. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23:2665-2674.
29. Nakamura T, Suzuki H, Wada Y, Kodama T, Doi T. Fucoidan induces nitric oxide production via p38 mitogen-activated protein kinase and NF-kappaB-dependent signaling pathways through macrophage scavenger receptors. Biochem Biophys Res Commun. 2006;343:286-294.
30. Relou AM, Gorter G, van Rijn HJ, Akkerman JW. Platelet activation by the apoB/E receptor-binding domain of LDL. Thromb Haemost. 2002;87:880-887.
31. Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res. 2002;69:567-577.
32. Lei ZB, Zhang Z, Jing Q, Qin YW, Pei G, Cao BZ, Li XY. OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc Res. 2002;53:524-532.
33. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, III, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (Berl). 2006;112:405-415.
34. Yanai H, Chiba H, Fujiwara H, Morimoto M, Abe K, Yoshida S, Takahashi Y, Fuda H, Hui SP, Akita H, Kobayashi K, Matsuno K. Phenotype-genotype correlation in CD36 deficiency types I and II. Thromb Haemost. 2000;84:436-441.
35. Matsubara E, Shoji M, Murakami T, Abe K, Frangione B, Ghiso J. Platelet microparticles as carriers of soluble Alzheimer's amyloid beta (sAbeta). Ann N Y Acad Sci. 2002;977:340-348.
36. Tan KT, Tayebjee MH, Lim HS, Lip GY. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med. 2005;22:1657-1662.
37. Koga H, Sugiyama S, Kugiyama K, Fukushima H, Watanabe K, Sakamoto T, Yoshimura M, Jinnouchi H, Ogawa H. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J. 2006;27:817-823.
38. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol. 2004;15:3-16.